ArticleBMC cancer2025

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC).

Francesca Aroldi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.